FORA Capital LLC Has $1.82 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

FORA Capital LLC lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 115.6% during the fourth quarter, HoldingsChannel reports. The firm owned 2,553 shares of the biopharmaceutical company’s stock after acquiring an additional 1,369 shares during the quarter. FORA Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $1,819,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Willner & Heller LLC increased its position in shares of Regeneron Pharmaceuticals by 3.9% during the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after acquiring an additional 15 shares in the last quarter. OLD Second National Bank of Aurora raised its stake in shares of Regeneron Pharmaceuticals by 0.5% in the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock valued at $2,025,000 after purchasing an additional 15 shares during the period. Rakuten Securities Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. TD Private Client Wealth LLC boosted its position in shares of Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 15 shares during the period. Finally, Manchester Capital Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 12.6% during the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 18 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 2.4 %

REGN opened at $547.55 on Friday. The stock has a market capitalization of $59.86 billion, a price-to-earnings ratio of 14.30, a P/E/G ratio of 2.34 and a beta of 0.43. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $520.50 and a twelve month high of $1,211.20. The company has a 50-day simple moving average of $616.03 and a 200 day simple moving average of $699.76.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue was down 3.7% on a year-over-year basis. During the same period last year, the company posted $9.55 EPS. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.96%.

Analyst Ratings Changes

REGN has been the topic of several research reports. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. Royal Bank of Canada cut their price objective on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 30th. The Goldman Sachs Group lowered their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. StockNews.com cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Finally, UBS Group reduced their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating for the company in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, five have given a hold rating, eighteen have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $892.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.